Author: Ravi Shankar

Press release – Regulated Information

Melexis: update on the share buy-back program

Ieper, Belgium – 21 September 2026, 17.45 hrs CET

Melexis reports the purchase of 14,519 Melexis shares on Euronext Brussels in the period from 14 September 2026 to 18 September 2026, related to the share buy-back program announced on 10 December 2025.

Trade date	Total shares purchased	Average price (€)	Min price (€)	Max price (€)	Buyback amount (€)
14/9/2026	4,500	63.78	63.00	64.70	287,016
15/9/2026	4,600	64.14	63.75	64.80	295,027
16/9/2026	4,500	64.93	64.70	65.00	292,191
17/9/2026	919	64.43	64.00	65.00	59,213
18/9/2026	–	–	–	–	–
TOTAL	14,519	64.29	63.00	65.00	933,447

Under the current share buy-back program for up to 850,000 shares, Melexis purchased 253,537 treasury shares.

Including 831,491 shares purchased under a previous share buy-back program, Melexis now holds 1,085,028 treasury shares.

Contact
Investor Relations
Email: investor@melexis.com

About Melexis
Melexis designs, develops, and delivers edge sensor and driver solutions with a heart for people and planet. Its mission is to empower engineers to turn their ideas into applications that support the best imaginable future, one that is safe, comfortable and sustainable. Melexis specializes in powertrain, thermal management, lighting, e-brake, e-steering and battery solutions for the automotive sector. It also expands its presence in the emerging markets of sustainable world, alternative mobility, robotics, and digital health.
Founded in 1989 in Belgium, Melexis has grown to employ approximately 2,000 people in 12 countries, delivering cutting-edge technology to customers worldwide.

For more information, visit www.melexis.com or follow Melexis on LinkedIn, and YouTube.

Disclaimer
Except for those statements that report the Company’s historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forward-looking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new product introductions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.

• By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD^1-3
• Susvimo helps people with nAMD maintain their vision with as few as two treatments per year^1-3
• Data from the Phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections²
• nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European Union^4,5

Basel, 21 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of vision loss in people over the age of 60.^5,6 

“The European Commission approval of Susvimo now provides this continuous delivery option to people in Europe with neovascular age-related macular degeneration,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Many nAMD patients are unable to extend their dosing interval beyond every eight weeks, and 40% discontinue treatment within two years. By offering patients continuous delivery through a refillable implant, Susvimo offers a unique alternative to frequent eye injections that can help maintain vision while significantly reducing the treatment burden.”

In 2025, Roche was granted a CE mark for its Port Delivery Platform, known as Contivue® in the European Union (EU), which comprises the eye implant that delivers Susvimo and four ancillary devices to initially fill, insert, refill, and remove the implant (if required).⁷ Contivue provides continuous delivery of Susvimo directly into the eye. Susvimo has been specifically developed for use with Contivue. Roche is evaluating other molecules in the pipeline that could potentially be used with the Port Delivery Platform to increase efficacy and/or durability, with the future aim of providing multiple treatment options to patients using Contivue.

“In clinical practice, we see firsthand how the fear of vision loss is compounded by the burden of frequent clinic visits,” said Frank Holz, Professor and Chairman of the Department of Ophthalmology at the University of Bonn, Germany. “By continuously delivering medicine directly into the eye, Contivue with Susvimo allows patients to maintain their vision with as few as two treatments a year.’’

The approval is based on data from three clinical studies in nAMD: one pivotal Phase III study, Archway, and two supportive studies, the Phase II Ladder study and the open-label long-term extension study Portal.^1-3 Data from Archway showed patients treated with Susvimo achieved and maintained vision outcomes equivalent to monthly intravitreal (IVT) ranibizumab injections, with longer-term data in Portal showing vision was maintained for up to seven years.^2,3 With two refills per year, approximately 95% of patients treated with Susvimo required no supplemental/additional anti-vascular endothelial growth factor (anti-VEGF) treatment.³ Susvimo was generally well tolerated over the longer term.^1-3

About neovascular age-related macular degeneration
Age-related macular degeneration (AMD) is a condition that affects the part of the eye that provides sharp, central vision needed for activities like reading. Neovascular or ‘wet’ AMD (nAMD) is an advanced form of the disease that can cause rapid and severe vision loss if left untreated.^8-10 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis.¹⁰ Worldwide, around 20 million people are living with nAMD – the leading cause of vision loss in people over the age of 60 – and the condition will affect even more people around the world as the global population ages.^5,8,11

About Contivue with Susvimo (Port Delivery Platform with ranibizumab)
The Contivue devices include a refillable implant surgically inserted into the eye during a one-time, outpatient procedure. Contivue also includes four ancillary devices to initially fill, insert, refill, and remove the implant.⁷

Contivue with Susvimo delivers a customised formulation of ranibizumab, Susvimo, over time.⁷ Ranibizumab is a VEGF inhibitor designed to bind to and inhibit VEGF-A, a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels.¹² The customised formulation of ranibizumab, Susvimo, delivered by Contivue with Susvimo is different from the ranibizumab IVT injection, a medicine marketed as Lucentis® (ranibizumab injection)*, which is approved to treat nAMD and other retinal disorders.¹³

In the US, the devices (refillable eye implant and ancillary devices) and medicine (customised formulation of ranibizumab) are approved by the Food and Drug Administration (FDA) as a single product, called Susvimo for the treatment of nAMD, diabetic macular edema (DME) and diabetic retinopathy (DR).¹⁴

Contivue with Susvimo is also approved for the treatment of nAMD in Switzerland and Thailand. 

About Roche in Ophthalmology
At Roche, we are on a mission to save and restore eyesight. Over 330 million people around the world are blind, or living with vision loss, creating a profound personal and socioeconomic burden.¹⁵ With the broadest pipeline in Ophthalmology, we continue to invest at scale to redefine what is medically possible in eye care.

Our comprehensive ophthalmology pipeline integrates diverse targets, advanced delivery systems, cell and gene therapies, and AI-augmented imaging capabilities, targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

*Lucentis® (ranibizumab injection) was developed by Genentech, a member of the Roche Group. Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world.

All trademarks used or mentioned in this release are protected by law.

References
[1] Khanani et al. First-Time Long-Term Efficacy and Safety Outcomes of PDS Patients Enrolled in the Ladder Phase 2 Trial of PDS for nAMD Followed for up to ~7 Years. 4-7 September, EURETINA 2025.
[2] Holekamp NM, Campochiaro PA, Chang MA, et al. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2022;129(3):295-307. doi:10.1016/j.ophtha.2021.09.016
[3] Kitchens J, et al. Five Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS. Presented at: The American Society of Retina Specialists (ASRS) 2025 Annual Meeting; 2025 August 01; Long Beach, California, United States.
[4] Li et al. Retinal diseases in Europe. Prevalence, incidence and healthcare needs. August 2017 [Internet; cited September 2026]. Available from: https://euretina.org/resource/euretina-whitebook-on-prevalence-incidence-and-healthcare-needs-for-retinal-diseases-in-europe/
[5] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-e116. doi:10.1016/S2214-109X(13)70145-1 
[6] Roche data on file.
[7] Roche. Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD). September 4, 2025. [Internet; cited September 2026]. Available from: https://www.roche.com/media/releases/med-cor-2025-09-04
[8] BrightFocus Foundation. Macular Degeneration Facts & Figures. [Internet; cited September 2026]. Available from: https://www.brightfocus.org/macular/facts-figures/
[9] Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond). 2016;3:34. doi:10.1186/s40662-016-0063-5
[10] Little K, Ma JH, Yang N, Chen M, Xu H. Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration – the potential sources and molecular cues for their recruitment and activation. EBioMedicine. 2018;38:283-291. doi:10.1016/j.ebiom.2018.11.029  
[11] Connolly E, Rhatigan M, O’Halloran AM, et al. Prevalence of age-related macular degeneration associated genetic risk factors and 4-year progression data in the Irish population. Br J Ophthalmol. 2018;102(12):1691-1695. doi:10.1136/bjophthalmol-2017-311673 
[12] Heier JS, Singh RP, Wykoff CC, et al. The angiopoietin/tie pathway in retinal vascular diseases: A review. Retina. 2021;41(1):1-19. doi:10.1097/IAE.0000000000003003
[13] European Medicines Agency. Lucentis (ranibizumab) Summary of Product Characteristics. May 2026. [Internet; cited September 2026]. Available from: https://www.ema.europa.eu/en/documents/product-information/lucentis-epar-product-information_en.pdf
[14] US Food and Drug Administration (FDA). Susvimo Prescribing Information. September 2025. [Internet; cited September 2026]. Available from: https://www.gene.com/download/pdf/susvimo_prescribing.pdf
[15] Bourne R, Steinmetz JD, Flaxman S, et al. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e130-e143.

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz Phone: +41 79 529 70 35	Lorena Corfas Phone: +41 79 568 24 95
Simon Goldsborough Phone: +44 797 32 72 915	Karsten Kleine Phone: +41 79 461 86 83
Kirti Pandey Phone: +41 79 398 38 53	Yvette Petillon Phone: +41 79 961 92 50
Irène Stephan Phone:  +41 79 377 83 75	Albert Thottiyil Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

• Media Investor Release EC approval Susvimo English

Certified, QA/QC-verified assay results from the first six HQ core holes of the 2026 Feasibility Study drilling program confirm broad, near-surface rare earth mineralization at the Cowboy State Mine, Red Mountain, with a pooled average grade of 3,497 ppm TREO (median 3,879 ppm) and a maximum single-sample assay of 9,084 ppm TREO over a 3.02 m interval in HC26-RM051. Approximately 93% of certified sampled intervals exceed the Company’s 1,000 ppm TREO Cowboy State Mine resource cut-off grade.

HIGHLIGHTS

• First certified assay results received from the 2026 Feasibility Study drilling program at the Cowboy State Mine, part of the Halleck Creek Rare Earths Project
• Six HQ diamond drill holes returned broad intervals of rare earth mineralization, confirming continuity of the existing geological model
• Mean pooled TREO grade of 3,497 ppm, with a median grade of 3,879 ppm TREO across reported intervals
• 93% of exploration intervals exceeded the resource cut-off grade of 1,000 ppm TREO, supporting the robustness of near-surface mineralization
• Highest reported assay returned 9,084 ppm TREO over 3.02 meters in hole HC26-RM051
• Hole HC26-RM056 returned 191 metres of continuous mineralization, representing one of the broadest mineralized intervals encountered in the current program
• Results remain outstanding from 12 additional holes completed as part of the 18-hole Feasibility Study drilling program

DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) — American Rare Earths Limited (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) (“ARR” or “the Company”) today reported certified assay results from ALS Global for the first six of eighteen planned HQ core drill holes of the ongoing 2026 Feasibility Study drilling program at the Cowboy State Mine area of the Halleck Creek Rare Earths Project in Wyoming.

The results reported herein represent certified, laboratory-verified analytical data for the initial six of eighteen planned HQ core drill holes drilled within the Cowboy State Mine development area at Red Mountain. Assay results have been reconciled to individual sample intervals, QA/QC-verified, and converted from certified elemental assays to rare earth oxide form using stoichiometric conversion factors consistent with the Company’s Halleck Creek technical documentation. Additional geological logging, QA/QC verification and laboratory results from the remaining twelve drill holes are expected over the coming weeks.

HIGHLIGHTS — INITIAL SIX HOLES FROM 2026 FEASIBILITY DRILLING

• Certified assay results have been received for the first six HQ core drill holes completed within the Cowboy State Mine development area at Red Mountain, representing the first analytical results from the 2026 Feasibility Study drilling program.
• The reported dataset comprises 386 unique geological assay intervals from six drill holes, with 20 QA/QC-only assays excluded from exploration-result statistics. Broad, near-surface rare earth mineralization was confirmed across all six holes, consistent with the Company’s existing geological model for the Cowboy State Mine deposit.
• Across the 386 geological assay intervals, TREO grades average 3,497 ppm, with a median grade of 3,879 ppm and a maximum single-sample assay of 9,084 ppm TREO over 3.02 m in HC26-RM051.
• Approximately 93% (358 of 386) of the reported geological assay intervals exceed the Company’s 1,000 ppm TREO Cowboy State Mine resource cut-off grade, demonstrating the broad distribution of rare earth mineralization encountered in the initial drilling.
• Significant continuous mineralized intervals calculated on the corrected 386-interval dataset are presented in Table 2, including broad mineralized intervals in all six reported holes.
• The initial six holes continue to demonstrate the broad, allanite-hosted rare earth mineralization characteristic of the Red Mountain intrusive complex and provide additional geological and analytical data to support ongoing Feasibility Study work at the Cowboy State Mine.
• Assay results from the remaining twelve planned HQ core holes are expected as laboratory processing, geological interpretation and QA/QC review continue.

INITIAL 2026 DRILL ASSAY RESULTS

Table 1 — Assay Highlights by Drill Hole (2026 HQ Core Program, ppm unless noted)

Drill Hole	Samples	Reported Interval (m)	TREO Mean	TREO Min	TREO Max	MREO Mean	LREO Mean	HREO Mean
HC26-RM051	57	128	3,469	844	9,084	995	2,912	557
HC26-RM052	61	116.7	3,347	450	5,268	934	2,923	424
HC26-RM053	63	119.3	3,046	123	7,717	855	2,690	356
HC26-RM054	51	118	3,553	442	4,836	997	3,124	428
HC26-RM055	57	117.9	3,744	843	5,382	1,045	3,200	543
HC26-RM056	97	189.3	3,726	224	6,939	1,038	3,355	371
Totals / Pooled Average	386	789.2	3,497	123	9,084	981	3,059	438

TREO: Total Rare Earth Oxide. MREO: Magnet Rare Earth Oxide (Pr6O11, Nd2O3, Sm2O3, Tb4O7, Dy2O3). LREO: Light Rare Earth Oxide. HREO: Heavy Rare Earth Oxide (includes Y2O3). “Samples” represents unique geological assay intervals; QA/QC-only standards, blanks and duplicate companion assays are excluded. Totals / Pooled Average row is a simple (non-length-weighted) mean, minimum and maximum across all 386 geological assay intervals.

The distribution of magnetic rare earth oxides (MREO) within the reported 2026 assay population is shown in Figure 1.

Figure 1 MREO Distribution for Red Mtn Assay Results

Table 2 — Significant Mineralized Intervals, 1,000 ppm TREO Cut-off

Composited using sample-length-weighted averaging of certified assays meeting a 1,000 ppm TREO cut-off — the same cut-off grade basis the Company applies to the current Cowboy State Mine Mineral Resource (ASX release, 19 November 2025). Internal dilution of up to 2.0 m of sub-cut-off material is allowed within an interval; minimum reportable interval length is 3.0 m. All reported intervals are downhole lengths; true width is not known for these holes (see Appendix A, Section 2, “Relationship between mineralisation widths and intercept lengths”).

Drill Hole	From (m)	To (m)	Interval (m)	Samples	TREO (wtd. avg)	MREO (wtd. avg)	LREO (wtd. avg)	HREO (wtd. avg)	TREO Min	TREO Max
HC26-RM051	0	99.44	99.44	45	3796	1088	3213	583	1091	9084
HC26-RM051	102.19	128.02	25.83	11	2837	863	2158	679	844	3385
HC26-RM052	5.79	108.42	102.63	53	3854	1079	3373	480	450	5268
HC26-RM052	116.33	124.97	8.64	4	3525	919	3265	260	1148	4689
HC26-RM053	3.96	69.89	65.93	31	3669	1073	3215	454	394	4363
HC26-RM053	84.37	124.76	40.39	18	3864	1016	3546	318	953	7717
HC26-RM054	0	12.1	12.1	5	3077	846	2683	394	2895	3330
HC26-RM054	14.33	92.75	78.42	33	4084	1151	3585	499	442	4836
HC26-RM054	96.56	122.03	25.47	10	3754	1045	3401	353	1868	4423
HC26-RM055	4.88	12.55	7.67	7	3630	1012	3060	570	2489	3928
HC26-RM055	15	125.02	110.02	46	4221	1179	3628	593	1193	5382
HC26-RM056	8.84	199.95	191.11	94	3951	1101	3570	381	224	6939

For comparison, a 1,500 ppm TREO cut-off (the basis used in the Company’s original February 2023 Halleck Creek release, applied to a different, RC-based drilling program) would yield fewer, generally shorter and higher-grade composites. The 1,000 ppm basis is used as the primary reporting basis in this release because it matches the cut-off grade currently applied to the Cowboy State Mine Mineral Resource, of which these holes form part.

Reported intervals are downhole lengths. Significant mineralized intervals were calculated using a 1,000 ppm TREO cut-off, allowing up to 2.0 m of internal dilution and requiring a minimum reported interval of 3.0 m. Interval grades are sample-length-weighted averages. True widths are not known.

The locations of the six drill holes reported herein, together with other completed and planned 2026 Red Mountain drill holes, are shown in Figure 2.

Figure 2 Red Mountain 2026 Drill Hole Locations

Representative down-hole TREO distributions for HC26-RM051 and HC26-RM056 are shown in Figures 3 and 4, respectively.

Figure 3 HC26-RM051 Cross Section Showing Down-Hole TREO Distribution

Figure 4 HC26-RM056 Cross Section Showing Down-Hole TREO Distribution

CONSISTENCY WITH THE HALLECK CREEK RESOURCE

The initial 2026 drill results are consistent with the broad grade distribution and near-surface mineralization represented in the existing Cowboy State Mine geological model and Mineral Resource Estimate:

• Across the six reported holes, the 386 geological assay intervals returned an average grade of 3,497 ppm TREO and a median grade of 3,879 ppm TREO. Approximately 93% (358 of 386) exceed the 1,000 ppm TREO cut-off used for the current Cowboy State Mine Mineral Resource, supporting the broad distribution of mineralization represented in the existing geological model.
• The predominance of samples above the 1,000 ppm TREO resource cut-off, together with the broad continuous mineralized intervals encountered in the initial holes, is consistent with the near-surface mineralization that underpins the conceptual open-pit development approach described in the February 2025 Updated Scoping Study¹.
• Higher-grade mineralization is also present within the broad mineralized envelope, including a maximum individual sample of 9,084 ppm TREO over 3.02 m in HC26-RM051. These results provide additional data on the distribution and continuity of higher-grade material within the Red Mountain portion of the Cowboy State Mine.

PROJECT OBJECTIVES AND FEASIBILITY STUDY IMPACT
The 2026 drilling program comprises up to approximately 2,877 meters of HQ core across 18 holes on Red Mountain, drilled by Boart Longyear, with Dahrouge Geological Consulting managing on-site logging and sample preparation. The program is expected to generate approximately 1,300 core samples for assay. The remaining core is being retained for geotechnical, hydrogeological, environmental and metallurgical test work supporting the Feasibility Study.

Twelve of the 18 completed holes target higher-grade zones near the top of Red Mountain within areas associated with the early conceptual mining sequence for the Cowboy State Mine. A total of 18 holes were completed, compared with 19 holes originally planned, following a mechanical issue with the drill rig during the final stages of the drilling program. These holes are intended to increase geological confidence and support future Mineral Resource classification and subsequent mine-planning studies. The other 6 planned holes are located around the base of Red Mountain to further evaluate higher-grade mineralization previously identified through channel sampling and geological mapping.

The initial results announced today provide additional geological and analytical information for the ongoing Feasibility Study workstream. Broad mineralized intervals encountered in the initial drilling provide data to support refinement of the geological model and evaluation of Mineral Resource classification within areas relevant to the proposed early mining sequence at the Cowboy State Mine.

NEXT STEPS
With certified assay results now reported for the first six of eighteen planned HQ core drill holes, analytical results from the remaining twelve holes are expected as laboratory processing and technical review continue. ARR’s technical team will continue to integrate the 2026 drilling results with geological logging, lithological interpretation and the existing Cowboy State Mine geological model as additional results become available.

Results from the remaining 2026 drill holes will be reported as certified assays become available and the Company’s standard technical and QA/QC review procedures are completed. The expanded drilling dataset will support ongoing geological modelling, evaluation of Mineral Resource classification, Feasibility Study activities, the Whole of Property Development Assessment (WPDA), and future Mineral Resource updates where appropriate.

MANAGEMENT COMMENTARY

“These first assays, from just the initial six of eighteen planned holes, are an encouraging start to the 2026 program. Approximately 93% of the reported samples exceed our 1,000 ppm TREO resource cut-off, with an average grade of 3,497 ppm TREO and a median grade of 3,879 ppm TREO. Just as importantly, we are seeing broad continuous mineralization across the initial holes, including 191 metres at 3,951 ppm TREO in HC26-RM056. With the balance of the program still to be reported, these results provide important additional data to support the geological model and ongoing Feasibility Study work at the Cowboy State Mine.”

– Mark Wall, Chief Executive Officer, American Rare Earths

“From a project execution standpoint, what stands out in this first tranche is the consistency and continuity of the mineralization. The drilling has returned broad mineralized intervals rather than isolated high-grade zones. That is an important characteristic as we continue to refine the geological model and advance the technical work supporting the Cowboy State Mine Feasibility Study.”

– Andrew Conover, Chief Development Officer, American Rare Earths

This announcement has been authorized for release by the Board of American Rare Earths Limited.

ABOUT THE HALLECK CREEK RARE EARTHS PROJECT

The Halleck Creek Rare Earths Project is located in Albany and Platte Counties, Wyoming, approximately 70 km northeast of Laramie and 30 km southwest of Wheatland. It hosts an allanite-dominant, near-surface REE system with a current JORC Mineral Resource Estimate of 2.63 billion tonnes at 3,292 ppm TREO for 8.65 million tonnes of contained rare earth oxides². Halleck Creek is being advanced through ARR’s wholly-owned U.S. subsidiary, Wyoming Rare (USA) Inc.

ABOUT AMERICAN RARE EARTHS LIMITED

American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) is developing a portfolio of U.S. rare earth assets anchored by the Halleck Creek Rare Earths Project in Wyoming, together with the La Paz project in Arizona and additional exploration projects at Beaver Creek in Wyoming and Searchlight in Nevada. The Company’s strategy is to build a domestic mine-to-oxide platform supplying critical rare earth oxides, including the NdPr magnet feed and strategic heavy rare earths, to U.S. defense, energy-transition and advanced-manufacturing customers. Further information is available at www.americanree.com.

For further information:

Investor Relations	Stock Information
Nick Lissolo	ASX: ARR
nlissolo@americanree.com	OTCQX: ARRNF
www.americanree.com	ADR: AMRRY

Media Contact:

Susan Assadi
sassadi@americanree.com
347 977 7125

Additional Investor Relations US Contact:

Beverly Jedynak
Beverly.jedynak@viriathus.com
312 943 1123

CAUTIONARY STATEMENT AND JORC DISCLOSURE
The Exploration Results reported in this announcement are based on certified laboratory assay results for the first six HQ core drill holes of the 2026 drilling program. A total of 406 assays are represented by the applicable laboratory certificates. Following reconciliation of the duplicate pairs, the reporting population comprises 386 unique geological assay intervals and 20 QA/QC-only assays (7 certified reference material standards, 7 blanks and 6 duplicate companion assays). QA/QC-only assays have been excluded from the exploration-result statistics reported herein, and no geological interval is counted twice.

Elemental rare earth assay results have been converted to rare earth oxide equivalents using the conversion factors described in Appendix A (JORC Table 1) and Appendix B. Cerium is reported as CeO2 using the Company’s established conversion convention (Ce × 1.2284). TREO is calculated as the sum of 15 reported rare earth oxides, with Sc2O3, ThO2 and UO2 excluded. MREO is calculated as Pr6O11 + Nd2O3 + Sm2O3 + Tb4O7 + Dy2O3. Significant mineralized intervals reported herein were calculated using a 1,000 ppm TREO cut-off, allowing up to 2.0 m of internal dilution and requiring a minimum reported interval of 3.0 m; interval grades are sample-length-weighted averages.

Mineral Resource Estimate information referenced in this release for the total Halleck Creek Project (2.63 Bt at 3,292 ppm TREO) and for the Cowboy State Mine (547.5 Mt at a 1,000 ppm TREO cut-off) is drawn from the Company’s prior ASX disclosures dated 4 February 2025 and 19 November 2025 respectively, and from the February 2025 Updated Scoping Study Technical Report prepared by Stantec Consulting Services Inc. The Company confirms that it is not aware of any new information or data that materially affects the information included in those releases, and that all material assumptions and technical parameters underpinning the estimates continue to apply.

The Scoping Study referred to in this announcement is a Class 5 AACE (±25–35%) preliminary technical and economic assessment and is not sufficient to support estimation of Ore Reserves or to provide assurance of an economic development case.

Forward-looking statements in this release, including references to Feasibility Study timing, resource conversion objectives and future assay results, are subject to risks and uncertainties, and actual results may differ materially.

COMPETENT PERSON STATEMENT

The information in this announcement that relates to Exploration Results is based on information compiled by Mark W. Travis, CPG, a Certified Professional Geologist and member of the American Institute of Professional Geologists (AIPG CPG-12090). Mr. Travis is an independent geological consultant to American Rare Earths Limited and has sufficient experience relevant to the style of mineralization and type of deposit under consideration, and to the activity being undertaken, to qualify as a Competent Person as defined in the 2012 Edition of the Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves (JORC Code). Mr. Travis consents to the inclusion in this announcement of the matters based on his information in the form and context in which they appear.

Full JORC announcement is here.

______________________________ 
¹ ASX Announcement dated 4 February 2025
² ASX Announcement dated 4 February 2025

Photo accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/10f0fc08-2547-4813-8209-7306c89de179

https://www.globenewswire.com/NewsRoom/AttachmentNg/b0fd4ca8-9706-4e63-8df8-48704ee3e756

https://www.globenewswire.com/NewsRoom/AttachmentNg/73340824-600e-4f1d-9850-0c0e7e77042c

https://www.globenewswire.com/NewsRoom/AttachmentNg/c93dd536-0317-4238-b8a7-4adeee85913e

Second campus under the Company’s 99 MW Alberta program; site offers 3 MW of grid power and a natural gas interconnection for behind-the-meter generation, planned as a 9.9 MW campus for AI and high-performance computing clients

WEST PALM BEACH, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) — FingerMotion, Inc. (Nasdaq: FNGR) (“FingerMotion” or the “Company”) today announced that its wholly owned subsidiary, Hanna Campus #1 Inc., has entered into a binding letter of intent to acquire approximately 20.2 acres of industrial land at 409 Pioneer Trail South in the Town of Hanna, Alberta.

Hanna Campus #1 is the second campus under the program the Company announced on September 10, 2026 to acquire and permit behind-the-meter power and compute sites in Alberta totaling approximately 99 MW across its Brooks, Coronation, Fox Creek and Vulcan Zones. The agreement was reached within two weeks of the program’s announcement. Each campus will be powered to suit the requirements of its offtake client, and the Company expects permitting, power and design for each campus to take approximately 120 to 180 days in total, in line with the timeline on which clients deliver their modular data halls. Each campus is sized below 10 MW to use the streamlined approval pathway for smaller power plants under Alberta Utilities Commission Rule 007, and each is to be held in its own subsidiary so that campuses can be permitted and contracted independently of one another.

The site has 3 MW of grid power available under an agreement with the Town of Hanna. It also has a natural gas interconnection through ATCO Energy to support behind-the-meter generation. The Company intends to develop the property as Hanna Campus #1, a 9.9 MW site within its Brooks Zone in central-east Alberta. Capacity will be contracted to AI and HPC clients under long-term agreements.

FingerMotion’s intended process is to secure land with power, permit it and contract capacity to offtake clients before committing construction capital. Offtake clients will be able to contract for the site as powered land on which they install their own data halls, as a colocation site, or as a turnkey facility. Grid power available at the site supports early energization, so the site can be utilized while behind-the-meter generation is being brought online.

“We believe that power is the main scarce commodity for AI and HPC capacity, which is why we will seek to contract for capacity before we initiate construction of a facility,” said Chris Polimeni, Chief Financial Officer of FingerMotion. “Hanna is the second campus in our 99 MW Alberta program, reached within two weeks of launching it. We expect it to be part of a series of campus announcements as the program advances.”

Development, permitting and construction will be carried out by BlueFlare Group Holdings Inc. (“BlueFlare”) of Calgary. BlueFlare is an oil and gas optimization, behind-the-meter power generation and EPC company specializing in modular data halls for AI/HPC. BlueFlare is the Company’s development partner across the 99 MW program.

Closing is subject to due diligence, execution of a definitive purchase agreement, and customary conditions.

About FingerMotion, Inc.

FingerMotion, Inc. (Nasdaq: FNGR) is a technology company historically focused on mobile payment, recharge, and data-analytics markets in the People’s Republic of China. Under current management, the Company is extending its strategy into enterprise AI and high-performance computing infrastructure in North America, including through its equity interest in Lyken AI Computing Inc., while evaluating its China operations.

Forward-Looking Statements.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s 99 MW Alberta development program, the timing and number of future campus announcements, the expected timeline for permitting, power and design of each campus, the closing of the acquisition, development of the site, generation capacity, permitting and client contracting.

These statements are based on management’s current expectations and are subject to significant risks and uncertainties that could cause actual results to differ materially, including failure to satisfy closing conditions, regulatory approvals, availability of financing, and the Company’s ability to secure offtake agreements. Additional risks include the Company’s ability to obtain permits on the anticipated timeline, to complete land acquisitions, to ratify or complete definitive documentation of the Strategic Development & Acquisition Agreement, to obtain project financing on acceptable terms or at all, to procure equipment as scheduled, to complete construction on budget, to secure natural gas supply, and to contract capacity on the commercial terms described or on any terms; changes in Alberta regulatory requirements; changes in commodity prices; competition; and the other risk factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact
Investor Relations
FingerMotion, Inc.
Email: ir@fingermotion.com

# # #

Company announcement No. 49 / 2026

Zealand Pharma – Transactions related to share buy-back program (week 38, 2026)

Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 38 (September 14 – September 18, 2026).

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference is made to company announcement no. 15 / 2026 dated May 7, 2026, which sets out the full terms of the Program. Under the Program, Zealand Pharma may repurchase shares for a total consideration of up to DKK 1.3 billion. The maximum number of shares that may be acquired under the Program is 7,152,557, and the Program commenced on May 7, 2026, and will be completed no later than October 31, 2026. The Company has appointed Danske Bank as lead manager for the Program. Danske Bank will make its own trading decisions independently of, and without influence from, the Company.

Transactions executed in week 38
The following transactions have been executed on Nasdaq Copenhagen (XCSE) under the Program during week 38 (September 14, 2026 – September 18, 2026):

Date	Number of shares	Average purchase price (DKK)	Transaction value (DKK)
Accumulated as per latest announcement	3,300,000		998,344,370
14/09/2026	70,000	282.39	19,767,300
15/09/2026	70,000	277.75	19,442,500
16/09/2026	70,000	274.13	19,189,100
17/09/2026	60,000	276.72	16,603,200
18/09/2026	55,000	283.64	15,600,200
Accumulated (W38)	325,000		90,602,300
Total accumulated under the Program	3,625,000		1,088,946,670

Treasury shares and share capital
Following the transactions described above, Zealand Pharma holds a total of 4,495,842 treasury shares, corresponding to approximately 6,28% of the Company’s share capital.

The total number of shares in Zealand Pharma is 71,610,005, each with a nominal value of DKK 1.

Additional information
Detailed information on each transaction executed under the Program is available in the appendix to this company announcement.

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
Zealand Pharma
Email: erojas@zealandpharma.com

Neshat Anis Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com

Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
Zealand Pharma
Email: rjamesowens@zealandpharma.com

Andreas Hylleberg Mølleskov (Media) 
Director, External Communications
Zealand Pharma
Email: ahylleberg@zealandpharma.com

Attachment

• Zealand Pharma – Share buy back – Transactions in week 38

GREENWICH, Conn., Sept. 21, 2026 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of freight transportation in North America, has been named to the 2027 FreightTech 100 list by FreightWaves, a global provider of supply chain market intelligence. XPO has been included on the FreightTech 100 every year since the inception of the list, which recognizes the most innovative companies in the freight transportation industry.

XPO’s operations are powered by cloud-based proprietary technologies that enable agility, efficiency and speed. Over the past year, the company has continued to introduce new AI applications while scaling proven tools across its network. These advances include broader deployment of AI-powered pickup-and-delivery route optimization, as well as new load photo analysis technology that gives frontline employees real-time feedback on trailer load quality. 

Jay Silberkleit, chief information officer of XPO, said, “Being named to the FreightTech 100 reflects our industry-leading technology and culture of continuous innovation. We’re building proprietary solutions that deliver actionable insights to our employees, helping us move freight more efficiently and deliver better service for our customers.”

The FreightTech 100 list was selected from hundreds of nominations by a panel of FreightWaves journalists, market analysts and researchers. XPO is one of only 11 companies that have made the list every year since 2020. 

About XPO
XPO, Inc. (NYSE: XPO) is a leader in asset-based less-than-truckload (LTL) freight transportation in North America. The company’s customer-focused organization efficiently moves 16 billion pounds of freight per year, enabled by its proprietary technology. XPO serves 55,000 customers with 586 locations and 38,000 employees in North America and Europe, and is headquartered in Greenwich, Conn., USA. Visit xpo.com for more information, and connect with XPO on LinkedIn, Facebook, X, Instagram and YouTube.

Investor Contact 
Brian Scasserra 
+1-617-607-6429 
brian.scasserra@xpo.com

Media Contact
Cole Horton
+1 203-609-6004
cole.horton@xpo.com 

Selection comes as campus celebrates 60 years serving the Dallas-Fort Worth Area

Parsippany, NJ, Sept. 21, 2026 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training, has announced its Grand Prairie, TX campus has been selected as a School of Excellence by the Accrediting Commission of Career Schools and Colleges (ACCSC). Each year ACCSC recognizes schools across the country that meet its highest standards for delivering quality career-focused education and training to students.

Lincoln Tech’s Grand Prairie campus has been part of the Dallas-Fort Worth’s education community since 1966. Career training is currently available for the Auto and Diesel Service, Electrical, HVAC-R and Welding industries – fields which are projected to add 2.6 million jobs across the country by 2034*. The campus is also home to the Hussmann Refrigeration TechX training center.

“We are honored to be selected by ACCSC for this award,” says Scott Shaw, Lincoln Tech’s President and CEO. “This demonstrates our commitment to student success while helping employers build stronger, competitive workforces. We’re grateful to ACCSC for recognizing our efforts, and we look forward to continuing to meet and exceed their standards and the expectations of our students and employer partners.”

“ACCSC is pleased to recognize Lincoln Tech in Grand Prairie, Texas as a School of Excellence,” says Dr. Michale McComis, ACCSC’s Executive Director. “This award underscores the school’s efforts to help students achieve high-quality skills and to make a difference in their lives in and in their community. Excellence matters and it does not come easily – that is why we spotlight it.”

ACCSC accredits 545 institutions throughout the United States and Puerto Rico, as well as internationally in Europe and Asia. Lincoln Tech’s Grand Prairie campus is one of just 18 schools to be recognized for this award.

* Career growth projections can be found at onetonline.org for the years 2024-2034 and are current as of August 25, 2026.

###

About Lincoln Educational Services Corporation

Lincoln Educational Services Corporation is a leading provider of diversified career-oriented post-secondary education. Lincoln offers recent high school graduates and working adults career-oriented programs in four principal areas of study: transportation, healthcare, skilled trades, and information technology. Lincoln has provided the workforce with skilled technicians since its inception in 1946.

Lincoln currently operates 22 campuses in 12 states under 3 brands: Lincoln College of Technology, Lincoln Technical Institute, and Nashville Auto-Diesel College.

For more information, go to lincolntech.edu. 

Attachments

• Lincoln Tech’s Grand Prairie campus has been part of the Dallas-Fort Worth education community since 1966
• Lincoln Tech focuses on student success

CONTACT: Scott Watkins, VP Marketing
Lincoln Tech
973.766.9656 
Swatkins@lincolntech.edu

NANJING, China, Sept. 21, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its pivotal registrational Phase IIb study of opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as monotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), has been selected as a Late-Breaking Abstract (LBA) and Proffered Paper presentation at the ESMO Congress 2026.

The selection highlights the clinical importance and scientific interest of the study and further demonstrates the growing international recognition of opamtistomig and Leads Biolabs’ clinical development capabilities. Notably, three Company-sponsored studies have been selected for Proffered Paper presentations at ESMO 2026, spanning EP-NEC and multiple myeloma.

Pivotal Phase IIb Study of Opamtistomig in Advanced EP-NEC Selected as Late-Breaking Abstract

The pivotal, registrational Phase IIb study is evaluating the efficacy and safety of opamtistomig monotherapy in patients with advanced EP-NEC who have received at least two prior lines of systemic therapy. The study generated key clinical data supporting the Company’s recent New Drug Application (NDA) submission to the National Medical Products Administration (NMPA).

Study Title:
Opamtistomig (LBL-024) monotherapy in advanced extra-pulmonary neuroendocrine carcinoma (EP-NEC) after >2 prior lines of therapies: results from a pivotal, registrational Phase IIb study of a novel PD-L1×4-1BB bispecific antibody

Presentation Type: Late-Breaking Abstract (LBA) / Proffered Paper

Principal Investigator: Professor Lin Shen, Peking University Cancer Hospital

Presenter: Dr. Ming Lu, Peking University Cancer Hospital

Presentation Time: 10:15-10:25, local time, 26 October

The ESMO 2026 LBA presentation will provide the pivotal clinical results from this study, offering further insights into the efficacy and safety profile of opamtistomig in this high unmet-need patient population.

Three Proffered Paper Presentations at ESMO 2026

In addition to the EP-NEC pivotal study, two other Leads Biolabs studies have been selected for Proffered Paper presentations at ESMO 2026:

• A pivotal registrational Phase IIb study of opamtistomig monotherapy in advanced EP-NEC, also selected as a Late-Breaking Abstract;
• A Phase Ib/II study of opamtistomig in combination with chemotherapy as first-line treatment for advanced EP-NEC; and
• A Phase I study of LBL-034 in patients with relapsed/refractory multiple myeloma (RRMM).

The selection of three studies for Proffered Paper presentations underscores the breadth of Leads Biolabs’ clinical development portfolio and its continued focus on advancing innovative therapies across areas of significant unmet medical need.

Broad ESMO 2026 Representation Across the Pipeline

In addition, four other Company-sponsored studies have been selected for poster presentations at ESMO 2026, covering clinical research of opamtistomig in biliary tract cancer (BTC), a mechanistic study in microsatellite-stable colorectal cancer (MSS CRC), and several meta-analyses.

Together, these presentations span clinical development, translational research and evidence synthesis, reflecting the breadth of Leads Biolabs’ oncology research portfolio and its commitment to generating high-quality clinical and scientific evidence.

Executive Commentary

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said: “The selection of our pivotal study of opamtistomig in advanced EP-NEC as a Late-Breaking Abstract at ESMO 2026 represents important recognition of the scientific and clinical interest in this program and the significant unmet need faced by patients with advanced EP-NEC. The selection of three Company-sponsored studies for Proffered Paper presentations further reflects the strength and breadth of our clinical development portfolio.

Opamtistomig is a cornerstone of our IO 2.0 strategy, and we are advancing its development across multiple tumor types and treatment settings. We remain focused on translating our differentiated PD-L1/4-1BB bispecific antibody approach into meaningful clinical benefits for patients and on advancing innovative treatment options for patients with cancer worldwide.”

About EP-NEC

Neuroendocrine carcinoma (NEC) is a highly malignant, immunologically “cold” tumor, accounting for approximately 10% to 20% of neuroendocrine neoplasms. NEC may arise in various organs, including the lung, gastrointestinal tract and bladder. NEC can be classified into pulmonary NEC and extrapulmonary NEC. EP-NEC shares the highly aggressive and metastatic characteristics of small cell lung cancer (SCLC), progresses rapidly, and most patients with NEC present with advanced-stage disease or distant metastases at diagnosis. Systemic treatment options for NEC are limited, with suboptimal efficacy and poor prognosis.

There are currently no therapies specifically approved by regulatory authorities worldwide for EP-NEC. First-line treatment for advanced EP-NEC primarily consists of platinum-based chemotherapy, with an objective response rate (ORR) of approximately 30% to 50% and a median overall survival (mOS) of only around one year. There is no standard treatment following progression on first-line therapy. Second-line treatment options may include oxaliplatin-based FOLFOX, irinotecan-based FOLFIRI, CAPTEM with or without bevacizumab, or temozolomide monotherapy. However, the efficacy of these treatment options remains limited, with an ORR of approximately 10% to 25% and an mOS of approximately eight months. Accordingly, there remains a substantial unmet medical need for patients with advanced EP-NEC, underscoring the urgent need for new and effective treatment options.

About Opamtistomig
Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Currently, opamtistomig is being evaluated in 14 indications, including one pivotal single-arm registrational study, one confirmatory Phase III study, and nine proof-of-concept studies, covering major indications such as NSCLC and multiple cold tumors. To date, opamtistomig has demonstrated robust antitumor activity across seven tumor types—extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), and ovarian cancer (OC)—highlighting its clinical value and broad therapeutic promise.

Developed using Leads Biolabs’ proprietary X-Body bispecific platform, opamtistomig is designed to simultaneously block PD-1/PD-L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic anti-tumor immune response. It has a safety profile comparable to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer potential. Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically “cold” tumors and potentially offering durable survival benefits.

Recognizing its clinical potential, opamtistomig received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA) in October 2024, and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in November 2024. Additionally, in January 2026, opamtistomig was granted Fast Track Designation (FTD) by the FDA and ODD by the European Commission, further underscoring its potential to address unmet medical needs in this patient population. In July 2026, its New Drug Application (NDA) was granted priority review designation by the NMPA, followed by NDA acceptance in August 2026, positioning opamtistomig as a potential world’s first approved 4-1BB-targeting antibody, the first approved agonist antibody, and the first approved treatment for EP-NEC.

About Leads Biolabs
Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally.

Leads Biolabs is a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 15 innovative drug candidates, including five clinical-stage drug candidates and one registration-stage asset.

The Company adopts a science-driven R&D approach and has successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. It has also developed multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued innovation and have been validated by the clinical outcomes of its bispecific antibody portfolios.

Leads Biolabs has established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of its drug candidates, coupled with its global perspectives, proactive strategy, and efficient clinical validation, have made it an attractive partner for leading industry players and investment institutions. For more information, please visit https://en.leadsbiolabs.com/

CONTACT: Contact:
yizi@leadsbiolabs.com

Not for distribution to U.S. newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, into the United States

Vancouver B.C., Sept. 21, 2026 (GLOBE NEWSWIRE) — TERRA CLEAN ENERGY CORP. (“Terra” or the “Company”) (CSE: TCEC, OTCQB: TCEFF, FSE: C9O0) is pleased to announce that the full amount of its previously announced brokered private placement has been fully allocated (see press release issued on September 8, 2026).

The offering is being conducted by Centurion One Capital Corp. as lead agent and sole bookrunner and is expected to close on or about October 5, 2026, subject to customary closing conditions and receipt of all required regulatory approvals, including approval of the Canadian Securities Exchange.

Under the offering, the Company expects to issue 14,285,714 units (the “Units”) at a price of $0.14 per Unit for aggregate gross proceeds of approximately $2,000,000.

Each Unit will consist of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share at an exercise price of $0.22 for a period of three years following the closing date.

“We are very pleased with the strong support received for this financing and the full allocation of the offering,” stated Greg Cameron, Chief Executive Officer of Terra Clean Energy. “The proceeds will allow us to fund the previously announced work program at our Marysvale Uranium Mines Project in Utah. Field crews are scheduled to mobilize during the final week of September to begin construction of the drill pads and excavation of the permitted trenches, positioning the Company for its planned 10,000-foot core drilling program.”

The net proceeds from the offering will be used primarily to fund the Company’s previously announced and permitted work program at the Marysvale Uranium Mines Project, including the construction of five drill pads, excavation of seven exploration trenches and preparations for the planned 10,000-foot core drilling program. A portion of the proceeds will also be used for general working capital purposes.

The securities issued under the offering will be subject to a statutory hold period of four months and one day from the closing date.

The offering remains subject to customary closing conditions and all necessary regulatory approvals. There can be no assurance that the offering will close on the terms described herein or at all.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

ABOUT TERRA CLEAN ENERGY CORP.

Terra Clean Energy Corp. is a Canadian-based uranium exploration and development company. The Company is currently developing the South Falcon East uranium project located in the Athabasca Basin region, Saskatchewan, Canada as well as past producing uranium mines in Utah and uranium exploration properties in Wyoming, United States. The Company’s strategy is to find and advance late-stage uranium projects to support growing demand for Nuclear Power and secure domestic mineral supply chains. 

For further information please visit Terra Clean Energy’s website at www.tcec.energy.

ABOUT CENTURION ONE CAPITAL CORP.

Centurion One Capital’s mission is to ignite the world’s most visionary entrepreneurs to conquer the greatest challenges of tomorrow, fueling their ambitions with transformative capital, unparalleled expertise, and a global network of influential connections. Every interaction is guided by our core values of respect, integrity, commitment, excellence in execution, and uncompromising performance. We make principal investments, drawing on the time-honored principles of merchant banking, where aligned incentives forge enduring partnerships. Centurion One Capital: A superior approach to investment banking.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For further information please contact:

Greg Cameron, CEO
info@tcec.energy
416-277-6174

Terra Clean Energy Corp
1133 Melville Street, Suite 2700
Vancouver, BC V6E 4E5
www.tcec.energy

Forward-Looking Information

This news release contains forward-looking information, including statements concerning the anticipated closing and completion of the offering, the receipt of regulatory approvals, the intended use of proceeds, the mobilization of field crews and the timing and scope of the Company’s planned exploration activities. Forward-looking information is based on assumptions considered reasonable by management as of the date of this release and is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update such information except as required by applicable securities laws.

Tarrytown, New York, USA, Sept. 21, 2026 (GLOBE NEWSWIRE) —

• People most at risk for MASLD/MASH remain largely unaware of the disease and its wider health risks
• Patients facing this metabolic condition benefit from early intervention
• The companies aim to remove barriers to non-invasive testing

Siemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). The companies are engaged in several projects to strengthen disease awareness, support earlier assessment of the disease, and help expand patient access to non-invasive blood testing.

MASLD is a metabolic condition that affects millions of people worldwide – nearly a quarter of U.S. adults – and is closely associated with obesity, type 2 diabetes, and cardiovascular disease.[1] MASLD has become the leading indication for liver transplant for women [1] and healthcare costs associated with the disease are projected to surpass $635 billion by the end of the decade.[2] Though MASLD is reversible if caught early, low disease awareness and its silent progression have led to many individuals remaining undiagnosed until significant liver damage occurs. In fact, people most at risk for MASLD remain largely unaware of the disease and its wider health risks.[3]

“Too often, liver health flies under the radar,” said Michele Zwickl, head of Laboratory Solutions for Siemens Healthineers North America. “People deserve the same level of awareness as for other major diseases, creating a better opportunity to intervene before serious complications develop.”  

Supporting earlier assessment and wider access through non-invasive testing

Assessment of liver fibrosis has relied heavily on specialized imaging equipment or invasive procedures such as liver biopsy, which are not widely accessible to patients. Clinicians recognize that liver biopsy remains necessary for certain patients, though there is growing consensus about the critical role that non-invasive tests play in the management of MASLD/MASH.[4,5]

As the global burden of metabolic disease rises, liver health experts are sounding the alarm about the importance of identifying the disease before it advances to fibrosis, cirrhosis, or other serious complications. The collaboration between Siemens Healthineers, a leading in vitro diagnostics company, and Novo, a global leader in cardiometabolic health, seeks to advance solutions that make MASH assessment more accessible and actionable across the healthcare continuum. This includes broader awareness and adoption of noninvasive testing (NIT) approaches that can provide clinicians with valuable information about liver health while helping reduce reliance on invasive procedures.

Among these approaches is a blood test from Siemens Healthineers. The Enhanced Liver Fibrosis (ELF®) test is the first and only blood test authorized in the United States to help clinicians assess risk of disease progression in patients with advanced fibrosis due to MASH and support patient management decisions. The simple test is available through major national laboratory providers and covered by a Category 1 CPT code (81517). Blood-based testing supports high patient demand and avoids failure rates and unreliable results reported for other non-invasive methods. For example, the ELF test results are not impacted by body composition characteristics such as BMI.

“Earlier triage is one of the most important opportunities to improve the future of MASH care,” said Michelle Long, senior international medical director for MASH at Novo. “Our collaboration recognizes that patients, clinicians, laboratories, health systems, and industry partners all have a role to play in creating a more effective pathway for liver disease assessment and management.”

###

1 Younossi ZM, et al. (2024) Epidemiology of metabolic dysfunction-associated steatotic liver disease
2 Suenghataiphorn T, et al. (2026) Future burden of MASLD in the United States: A state-level forecasting study
3 According to a survey of 1,000 U.S.‑based adults most at risk for MASLD based on the disease’s screening criteria. Conducted by YouGov on behalf of Siemens Healthineers.
4 Lam, BP, et al. (2025) Focused recommendations for the management of metabolic dysfunction-associated steatohepatitis (MASH) by advanced practice providers in the United States
5 Advancing liver care with non-invasive tests (Part 2) https://podcasts.apple.com/de/podcast/advancing-liver-care-with-non-invasive-tests-part-2/id1618029606?i=1000712407598

Contact Info

Kimberly Nissen
kimberly.nissen@siemens-healthineers.com
+1 610-241-2129

Attachment

• Siemens Healthineers Novo Collab Press Release